Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ICOTINIB for Lung adenocarcinoma: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 8 adverse event reports in the FDA FAERS database where ICOTINIB was used for Lung adenocarcinoma.

Most Reported Side Effects for ICOTINIB

Side Effect Reports % Deaths Hosp.
Rash 14 34.2% 1 1
Hypertension 12 29.3% 0 0
Diarrhoea 10 24.4% 0 0
Malignant neoplasm progression 10 24.4% 2 2
Fatigue 9 22.0% 1 0
Bone marrow failure 7 17.1% 0 1
Proteinuria 7 17.1% 0 0
Vomiting 7 17.1% 2 0
Disease progression 6 14.6% 0 0
Haemorrhage 6 14.6% 0 0
Nausea 6 14.6% 2 0
Anaemia 5 12.2% 0 0
Leukopenia 5 12.2% 0 0
Liver injury 5 12.2% 0 1

Other Indications for ICOTINIB

Non-small cell lung cancer (15)

Other Drugs Used for Lung adenocarcinoma

PEMETREXED (4,280) PEMBROLIZUMAB (3,954) CARBOPLATIN (3,888) BEVACIZUMAB (1,522) PACLITAXEL (1,216) NIVOLUMAB (1,162) ATEZOLIZUMAB (1,032) CISPLATIN (1,003) DOCETAXEL (977) OSIMERTINIB (936)

Related Pages

ICOTINIB Full Profile All Lung adenocarcinoma Drugs ICOTINIB Demographics ICOTINIB Timeline